Pridopidine Demonstrates Slowing of Progression of Huntington Disease in PRIDE-HD Study as Measured by Total Functional Capacity

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announces top-line results from the exploratory Phase 2 PRIDE-HD study. This was a 52-week, dose-ranging trial of pridopidine twice daily versus placebo, in the treatment of Huntington disease (HD). The study was directed at measuring improvement in motor function and the effect on HD progression.

SD-809 demonstrates a statistically significant improvement in Abnormal Involuntary 
Movement Scale score in AIM-TD study

Adds to body of data supporting this promising breakthrough investigational therapy to 
address unmet patient need

Platform aims to enhance understanding of disease progression and impact of treatment

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announces a collaboration with Intel Corporation to develop a unique wearable device and machine learning platform for use in Huntington disease (HD). This platform will continuously monitor and analyze key symptoms that impact daily living, in an effort to better understand disease progression and improve treatment evaluation.